



Nath Bio-Genes (I) Ltd.

(CIN L01110MH1993PLC072842)

August 4th, 2016

To,

The Secretary,
Bombay Stock Exchange Ltd
Phiroze Jeejeebhoy Towers
Dalal Street, MUMBAI 400 001

The Secretary,
National Stock Exchange of India Ltd
Exchange Plaza, 5th Floor
Plot No. C/1, G Block
Bandra-Kurla Complex
Bandra (E), MUMBAI 400 051

The Secretary,
Ahmedabad Stock Exchange Ltd
Kamdhenu Complex
Opp Sahajanand College
Panjarpole, AHMEDABAD 380 015

SCRIP CODE NO: 537291

Sub: Submission of information under Clause 33(3) (c) of the SEBI (LORD) Regulations, 2015.

Dear Sir,

Please find enclosed herewith Limited Review Report for the quarter ended June 30th, 2016.

The above information is being provided to you under Clause 33(3) (c) of the SEBI (LORD) Regulations, 2015.

This is for your information and record purpose.

Thanking You.

Yours faithfully,
For Nath Bio-Genes (India) Limited,

Authorised Signatory



Gautam N Associates
Chartered Accountants


30, GNA House, Behind ABC Complex,
Manmandir Travels Lane, Adalat Road, Aurangabad-431001

LIMITED REVIEW REPORT

To
The Board of Directors of
NATH BIO-GENES (INDIA).LIMITED.

1. We have reviewed the accompanying statement of unaudited financial results for the quarter ended 30th June 2016 (the Statement) of NATH BIO-GENES (INDIA) LIMITED (the Company) except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoters Group Shareholding, which have been traced from the disclosure made by the management and have not been reviewed by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material mis-statement. A review is limited primarily to enquiries of the company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with recognition and measurement principles laid down in Accounting Standard -25 "Interim Financial Reporting", specified under the Companies Act, 1956 (which are deemed to be applicable as per Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014) and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of clause -33 of SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015 including the manner in which it is to be disclosed, or that it contains any material mis-statement.

For Gautam N Associates
Chartered Accountants
FRN : 103117W


(Gautam Nandawat)
Partner
M N :032742



Place: Aurangabad
Dated: 29th July, 2016



Nath Bio-Genes (I) Ltd.

(CIN L01110MH1983PLC072822)

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30/06/2016

Rs in Lacs						
	Three Months Ended			Three Months Ended		Year Ended
	30/06/2016 Unaudited	31/03/2016 Audited	30/06/2015 Unaudited	30/06/2016 Unaudited	30/06/2015 Unaudited	31/03/2016 Audited
1 Net Sales / Income from operations	8432.99	2829.33	9454.59	8432.99	9454.59	16210.59
2 Expenses						
a) Changes in Inventory	1764.61	(649.32)	9.67	1764.61	9.67	(2442.00)
b) Cost of Material Consumed	1981.45	1045.67	3979.92	1981.45	3979.92	7795.86
c) Employee benefit expense	443.78	213.83	492.12	443.78	492.12	1363.44
d) Selling & Distribution Expenses	2063.03	1224.44	1949.62	2063.03	1949.62	5032.64
e) Depreciation & Amortisation	100.00	(0.95)	110.00	100.00	110.00	390.48
f) Other Expenditure	208.32	1264.10	343.29	208.32	343.29	2008.27
g) Total	6561.19	3097.77	6884.62	6561.19	6884.62	14148.69
3 Profit from Operations before Other Inc	1871.80	(268.44)	2569.97	1871.80	2569.97	2061.90
4 Other Income	11.98	46.48	3.63	11.98	3.63	84.64
5 Profit before Interest & Other Items	1883.77	(221.96)	2573.60	1883.77	2573.60	2146.54
6 Finance Costs	234.28	65.90	169.19	234.28	169.19	623.08
7 Profit before Exceptional Items	1649.49	(287.86)	2404.41	1649.49	2404.41	1523.45
8 Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
9 Profit/(Loss) before Tax	1649.49	(287.86)	2404.41	1649.49	2404.41	1523.45
10 Tax expense	0.00	71.00	0.00	0.00	0.00	104.82
11 Net Profit / (Loss) after Tax	1649.49	(358.86)	2404.41	1649.49	2404.41	1418.63
12 Extraordinary Items	0.00	0.04	0.00	0.00	0.00	1.88
13 Net Profit / (Loss) for the period	1649.49	(358.90)	2404.41	1649.49	2404.41	1416.75
14 Share of Profit/(Loss) of Associates	0.00	0.00	0.00	0.00	0.00	0.00
15 Minority Interest	0.00	0.00	0.00	0.00	0.00	0.00
16 Net Profit/(Loss) after Associates	1649.49	(358.90)	2404.41	1649.49	2404.41	1416.75
17 Paid Up Equity Share Capital (Face Value Rs. 10/- each)	1600.40	1600.40	1600.40	1600.40	1600.40	1600.40
18 Reserves (excluding Revaluation)	12179.49	10530.00	11517.66	12179.49	11517.66	10530.00
19 Basic and Diluted EPS	10.31	(2.24)	15.02	10.31	15.02	8.85
Particulars of Shareholding						
Public Shareholding						
No of Shares	7779456	7779456	8351468	7779456	8351468	7779456
% of Shareholding	48.61	48.61	52.18	48.61	52.18	48.61
Promoters and Promoter group						
a) Pledged/Encumbered						
No of Shares	6665287	5920287	4420287	6665287	4420287	5920287
% of Shares (as a % of the total shareholding of promoter and promoter)	81.04	71.98	57.76	81.04	57.76	71.98
% of Shares (as a % of the total share capital of the Company)	41.65	36.99	27.62	41.65	27.62	36.99
b) Non Encumbered						
No of Shares	1559257	2304257	3232245	1559257	3232245	2304257
% of Shares (as a % of the total shareholding of promoter and promoter)	18.96	28.02	42.24	18.96	42.24	28.02
% of Shares (as a % of the total share capital of the Company)	9.74	14.40	20.20	9.74	20.20	14.40

NOTES : (1) Above financial results were taken on record by the Board of Directors in their meeting held on 29th July 2016. (2) The Company's business is seasonal in nature. Because of the delayed monsoons, the Kharif season of 2016 has extended into the second quarter. Hence the quarterly results are not necessarily comparable. (3) The company is dealing in one major product segment. (4) The Company has made appropriate provisions for likely sales returns, schemes and incentives for the quarter. (5) Investor complaints - Opening Balance - 0, Received and Solved - 2, Closing Balance - 0 (6) The earlier period figures have been regrouped /

FOR NATH BIO-GENES (INDIA) LTD

Place : Aurangabad
Date : 29th July 2016


Satish Kagiwal
MANAGING DIRECTOR
DIN 00119601

Regd. Office: Nath House, Nath Road, Aurangabad - 431005 (MS)
www.nathbiogenes.com



FOR GAUTAM N ASSOCIATES
CHARTERED ACCOUNTANTS

Nath Bio-Genes (India) Limited
Standalone Statement of Assets and Liabilities

Rs. In Lacs

Particulars	As at 30.06.2016 (Unaudited)	As at 31.03.2016 (Audited)
A EQUITIES AND LIABILITIES		
1. Shareholders' Fund	1600.40	1600.40
(a) Share capital	12179.49	10530.00
(b) Reserves and Surplus	0.00	0.00
(c) Money received against share warrants	13779.89	12130.40
Sub-total - Shareholders' Fund	0.00	0.00
2. Share application money pending for allotment	0.00	0.00
3. Minotiries Interest		
4. Non-current liabilities	1500.00	1500.00
a) Long Term Borrowings	0.00	0.00
b) Deferred Tax Liabilities	0.00	0.00
c) Other Long Term Liabilities	186.23	178.64
d) Long Term Provisions	1686.23	1678.64
Sub-total - Non-current liabilities		
5. Current Liabilities	4456.03	4304.48
a) Short Term Borrowings	4160.07	4795.13
b) Trade Payables	3722.85	3540.21
c) Other Current Liabilities	223.56	221.15
d) Short Term Provisions	12562.51	12860.97
Sub-total - Current liabilities	28028.63	26670.01
TOTAL - EQUITY AND LIABILITIES		
B ASSETS		
(1) Non Current Assets	2948.71	3046.36
a) Fixed Assets	0.26	0.26
b) Non Current Investments	86.86	86.86
c) Deferred Tax Assets (Net)	1033.40	1009.51
d) Long Term Loans and Advances	0.00	0.00
e) Other Non Current Assets	4069.23	4142.99
Sub-total - Non Current Assets		
(2) Current Assets	499.40	499.40
a) Current Investments	12197.79	14073.98
b) Inventories	7897.70	4531.14
c) Trade Receivables	269.81	122.44
d) Cash and Cash Equivalents	2992.87	3184.75
e) Short Term Loans and Advances	101.83	115.31
f) Other Current Assets	23959.40	22527.02
Sub-total - Current Assets	28028.63	26670.01
TOTAL ASSETS	0	0

FOR NATH BIO-GENES (INDIA) LTD

Place : Aurangabad
Date : 29th Jul 2016

Satish Kagiwal
MANAGING DIRECTOR
DIN 00119601



FOR GAUTAM N ASSOCIATES
CHARTERED ACCOUNTANTS
Gautam
GAUTAM NANDAWAT
(Partner)